You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
|
|---|---|
| Published in |
Nature Medicine, September 2015
|
| DOI | 10.1038/nm.3952 |
| Pubmed ID | |
| Authors |
Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, Timo Kuschma, Stephan A Hahn, Deepak Vangala, Marija Trajkovic-Arsic, Aayush Gupta, Irina Heid, Peter B Noël, Rickmer Braren, Mert Erkan, Jörg Kleeff, Bence Sipos, Leanne C Sayles, Mathias Heikenwalder, Elisabeth Heßmann, Volker Ellenrieder, Irene Esposito, Tyler Jacks, James E Bradner, Purvesh Khatri, E Alejandro Sweet-Cordero, Laura D Attardi, Roland M Schmid, Guenter Schneider, Julien Sage, Jens T Siveke |
| Abstract |
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and shows resistance to any therapeutic strategy used. Here we tested small-molecule inhibitors targeting chromatin regulators as possible therapeutic agents in PDAC. We show that JQ1, an inhibitor of the bromodomain and extraterminal (BET) family of proteins, suppresses PDAC development in mice by inhibiting both MYC activity and inflammatory signals. The histone deacetylase (HDAC) inhibitor SAHA synergizes with JQ1 to augment cell death and more potently suppress advanced PDAC. Finally, using a CRISPR-Cas9-based method for gene editing directly in the mouse adult pancreas, we show that de-repression of p57 (also known as KIP2 or CDKN1C) upon combined BET and HDAC inhibition is required for the induction of combination therapy-induced cell death in PDAC. SAHA is approved for human use, and molecules similar to JQ1 are being tested in clinical trials. Thus, these studies identify a promising epigenetic-based therapeutic strategy that may be rapidly implemented in fatal human tumors. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 24% |
| United Kingdom | 2 | 7% |
| New Zealand | 1 | 3% |
| France | 1 | 3% |
| China | 1 | 3% |
| Unknown | 17 | 59% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 48% |
| Scientists | 6 | 21% |
| Practitioners (doctors, other healthcare professionals) | 5 | 17% |
| Science communicators (journalists, bloggers, editors) | 4 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 383 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Austria | 2 | <1% |
| France | 2 | <1% |
| Netherlands | 1 | <1% |
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Iran, Islamic Republic of | 1 | <1% |
| Belgium | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 373 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 78 | 20% |
| Researcher | 72 | 19% |
| Student > Master | 42 | 11% |
| Student > Bachelor | 35 | 9% |
| Student > Doctoral Student | 23 | 6% |
| Other | 54 | 14% |
| Unknown | 79 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 102 | 27% |
| Agricultural and Biological Sciences | 86 | 22% |
| Medicine and Dentistry | 63 | 16% |
| Chemistry | 13 | 3% |
| Immunology and Microbiology | 11 | 3% |
| Other | 23 | 6% |
| Unknown | 85 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 106. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2017.
All research outputs
#403,994
of 26,017,215 outputs
Outputs from Nature Medicine
#1,408
of 9,421 outputs
Outputs of similar age
#5,375
of 289,192 outputs
Outputs of similar age from Nature Medicine
#8
of 77 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 105.2. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,192 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.